BPI-7701, a Covalent Mutant-Selective EGFR Inhibitor, Inhibits the Growth of NSCLC Lines with EGFR Activating and T790M Resistance Mutations

被引：0
|
作者：
Wilde, Victoria L. [1 ]
Zhang, Don X. [1 ]
Peng, Jirong [1 ]
Greco, Michael N. [1 ]
Green, Michael A. [1 ]
Costanzo, Michael J. [1 ]
机构：
[1] Beta Pharma Usa Inc, Res & Dev, Princeton, NJ USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
NSCLC; EGFR; T790M;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-016
引用
收藏
页码：S526 / S527
页数：2
相关论文
共 50 条
  • [1] Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression
    Tanaka, Hiroaki
    Sakagami, Hideki
    Kaneko, Naoki
    Konagai, Satoshi
    Yamamoto, Hiroko
    Matsuya, Takahiro
    Yuri, Masatoshi
    Yamanaka, Yosuke
    Mori, Masamichi
    Takeuchi, Masahiro
    Koshio, Hiroyuki
    Hirano, Masaaki
    Kuromitsu, Sadao
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (08) : 1366 - 1373
  • [2] Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
    Walter, Annette O.
    Sjin, Robert Tjin Tham
    Haringsma, Henry J.
    Ohashi, Kadoaki
    Sun, Jing
    Lee, Kwangho
    Dubrovskiy, Aleksandr
    Labenski, Matthew
    Zhu, Zhendong
    Wang, Zhigang
    Sheets, Michael
    St Martin, Thia
    Karp, Russell
    van Kalken, Dan
    Chaturvedi, Prasoon
    Niu, Deqiang
    Nacht, Mariana
    Petter, Russell C.
    Westlin, William
    Lin, Kevin
    Jaw-Tsai, Sarah
    Raponi, Mitch
    Van Dyke, Terry
    Etter, Jeff
    Weaver, Zoe
    Pao, William
    Singh, Juswinder
    Simmons, Andrew D.
    Harding, Thomas C.
    Allen, Andrew
    CANCER DISCOVERY, 2013, 3 (12) : 1404 - 1415
  • [3] Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
    Zhou, Wenjun
    Ercan, Dalia
    Chen, Liang
    Yun, Cai-Hong
    Li, Danan
    Capelletti, Marzia
    Cortot, Alexis B.
    Chirieac, Lucian
    Iacob, Roxana E.
    Padera, Robert
    Engen, John R.
    Wong, Kwok-Kin
    Eck, Michael J.
    Gray, Nathanael S.
    Jaenne, Pasi A.
    NATURE, 2009, 462 (7276) : 1070 - 1074
  • [4] Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
    Wenjun Zhou
    Dalia Ercan
    Liang Chen
    Cai-Hong Yun
    Danan Li
    Marzia Capelletti
    Alexis B. Cortot
    Lucian Chirieac
    Roxana E. Iacob
    Robert Padera
    John R. Engen
    Kwok-Kin Wong
    Michael J. Eck
    Nathanael S. Gray
    Pasi A. Jänne
    Nature, 2009, 462 : 1070 - 1074
  • [5] Preclinical assessment of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
    Simmons, Andrew D.
    Haringsma, Henry J.
    Walter, Annette O.
    Sjin, Robert Tjin Tham
    Weaver, Zoe
    Allen, Andrew
    Harding, Thomas C.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [6] Novel T790M mutant-selective EGFR kinase inhibitors
    不详
    PHARMACOGENOMICS, 2010, 11 (06) : 744 - 744
  • [7] Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
    Jia, Yong
    Yun, Cai-Hong
    Park, Eunyoung
    Rcan, Dalia E.
    Manuia, Mari
    Juarez, Jose
    Xu, Chunxiao
    Rhee, Kevin
    Chen, Ting
    Zhang, Haikuo
    Palakurthi, Sangeetha
    Jang, Jaebong
    Lelais, Gerald
    DiDonato, Michael
    Bursulaya, Badry
    Michellys, Pierre-Yves
    Epple, Robert
    Marsilje, Thomas H.
    McNeill, Matthew
    Lu, Wenshuo
    Harris, Jennifer
    Bender, Steven
    Wong, Kwok-Kin
    Janne, Pasi A.
    Eck, Michael J.
    NATURE, 2016, 534 (7605) : 129 - +
  • [8] Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
    Yong Jia
    Cai-Hong Yun
    Eunyoung Park
    Dalia Ercan
    Mari Manuia
    Jose Juarez
    Chunxiao Xu
    Kevin Rhee
    Ting Chen
    Haikuo Zhang
    Sangeetha Palakurthi
    Jaebong Jang
    Gerald Lelais
    Michael DiDonato
    Badry Bursulaya
    Pierre-Yves Michellys
    Robert Epple
    Thomas H. Marsilje
    Matthew McNeill
    Wenshuo Lu
    Jennifer Harris
    Steven Bender
    Kwok-Kin Wong
    Pasi A. Jänne
    Michael J. Eck
    Nature, 2016, 534 : 129 - 132
  • [9] TAS-2913 is a Mutant Selective EGFR Inhibitor for NSCLC: Characterization Against EGFR T790M in Cell and Xenograft Models
    Miyadera, K.
    Kato, M.
    Takahashi, I.
    Ito, K.
    Aoyagi, Y.
    Fukasawa, K.
    Sagara, T.
    Yonekura, K.
    Iwasawa, Y.
    Utsugi, T.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 44 - 44
  • [10] ASP8273, a novel mutantselective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations
    Sakagami, Hideki
    Konagai, Satoshi
    Yamamoto, Hiroko
    Tanaka, Hiroaki
    Matsuya, Takahiro
    Mori, Masamichi
    Koshio, Hiroyuki
    Yuri, Masatoshi
    Hirano, Masaaki
    Kuromitsu, Sadao
    CANCER RESEARCH, 2014, 74 (19)
12345